AOTMiT: The Transparency Council will evaluate drugs in oncology, ophthalmology and hematooncology, among others

Agenda

1. Preparation of a position paper on the evaluation of the drug Beyonttra (acoramidisum)
   under drug program B.162 "Treatment of patients with cardiomyopathy (ICD-10: E85, I42.1)".
2. Preparation of a position paper on the evaluation of the drug Darzalex (daratumumabum)
   under drug program B.54 "Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)".
3. Preparation of an opinion on the draft health policy program of JST
   "Prevention in the field of cataract and glaucoma diagnostics and AMD - macular degeneration for the residents of the municipality of Konstancin-Jeziorna for the year 2026".
4. Preparation of an opinion on the active substance sunitinibum - off-label indications
   (Annex C.88.a., pediatric population)
   ICD-10 scope:
   
   • Esophagus: C15.0, C15.1, C15.2, C15.3, C15.4, C15.5, C15.8, C15.9
   • Stomach: C16.0, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9
   • Small intestine: C17.0, C17.1, C17.2, C17.3, C17.8, C17.9
   • Bowel/rectum: C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20
   • Retroperitoneal space/peritoneum: C48.0, C48.1, C48.2, C48.8

1. Preparation of an opinion on the active substance imatinibum - off-label indications
   (Annex C.70.d., pediatric population)
   ICD-10 scope:
   
   • Esophagus: C15.0, C15.1, C15.2, C15.3, C15.4, C15.5, C15.8, C15.9
   • Stomach: C16.0, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9
   • Small intestine: C17.0, C17.1, C17.2, C17.3, C17.8, C17.9
   • Bowel/rectum: C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20
   • Retroperitoneal space/peritoneum: C48.0, C48.1, C48.2, C48.8

1. Preparation of an opinion on the active substance sorafenibum - off-label indication
   (Annex C.89.a.) in adult patients with histologically confirmed advanced/metastatic gastrointestinal lining tumor (GIST), after treatment failure with imatinib and sunitinib
   ICD-10 scope:
   
   • Esophagus: C15.0, C15.1, C15.2, C15.3, C15.4, C15.5, C15.8, C15.9
   • Stomach: C16.0, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9
   • Small intestine: C17.0, C17.1, C17.2, C17.3, C17.8, C17.9
   • Bowel/rectum: C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20
   • Retroperitoneal space/peritoneum: C48.0, C48.1, C48.2, C48.8

1. Preparation of an opinion on the active substance brentuximabum vedotinum - off-label indications
   
   • B.77: differentiation of the dosage description according to the age of patients in the indication: relapsed or refractory Hodgkin's lymphoma (HL) - pediatric population.
   • B.66: differentiate the dosage description according to the age of patients in the indication: relapsed or refractory CD30+ systemic anaplastic large cell lymphoma (sALCL) - pediatric population.

Source: AOTMiT